The aesthetics industry has rarely stood still. Treatments that once sat at the margins of cosmetic medicine have moved steadily into the mainstream, while a constant stream of newer procedures promises everything from improved skin texture to “cellular regeneration”. But separating lasting shifts in consumer behaviour from short-lived enthusiasm is not straightforward.

One way of reading those changes is through search data. Analysis of Google search trends in Great Britain between October 2023 and June 2026 points to an industry that is still expanding, but also subtly reorganising itself.

Established injectables remain central to public interest, while the strongest growth is increasingly concentrated in treatments focused on skin quality and repair rather than visible structural change.

The picture is not one of replacement, but of layering: newer regenerative treatments growing alongside, rather than instead of, familiar procedures.

Botox and the normalisation of injectables

Perhaps the most consistent feature of the data is the continued strength of interest in Botox, the brand name that has become shorthand for anti-wrinkle injections more broadly.

Search interest rose steadily over the period, increasing by roughly a third between late 2023 and mid-2026. During that time it also reached a peak in early 2026, marking its highest level of public attention in the dataset.

What is notable is less the pace of growth than its stability. Botox appears to have moved beyond novelty cycles or trend-driven spikes. Instead, it occupies a more embedded position in public awareness — discussed openly on social media, routinely offered in clinics, and increasingly framed as part of general aesthetic maintenance rather than dramatic cosmetic intervention.

As Sophie Brady, owner of Sculptaire Aesthetics, puts it: “We’ve moved past the point where Botox is something people feel they need to justify. For many clients, it’s become part of the same conversation as skincare or hair appointments — it’s maintenance, not transformation.”

That stability also defines its commercial role. It remains the central driver of footfall for most clinics, but no longer represents a fast-expanding frontier in itself.

A mature fillers market

The picture for dermal fillers is more subdued.

Search interest in generic fillers showed little meaningful change over the period studied, remaining broadly flat. This suggests a category that expanded rapidly in earlier years and has since stabilised. Lip fillers showed slightly more movement, rising modestly over the period, but within a relatively narrow historical range.

Taken together, the data points towards a market that has reached a kind of equilibrium. Fillers remain widely used and culturally visible, but they no longer appear to be generating the same momentum they once did during their period of rapid expansion.

That shift also reflects broader changes in aesthetic preference. Rather than dramatic volume enhancement, there appears to be growing interest in more subtle outcomes — particularly those associated with skin texture, elasticity and overall skin health.

Microneedling and the turn towards skin quality

If one treatment stands out in the data, it is microneedling.

Search interest more than doubled between late 2023 and mid-2026, with particularly strong growth through 2025 and into 2026. While still not at the scale of Botox or fillers in absolute terms, its trajectory is notably steeper than most established treatments.

Microneedling’s appeal appears closely tied to its positioning. Rather than adding volume or altering facial structure, it is framed around stimulating the skin’s own repair processes through collagen production and controlled micro-injury.

That emphasis on “working with the body” rather than reshaping it aligns with a wider shift in aesthetics towards regenerative and maintenance-based treatments. Related technologies, particularly radiofrequency microneedling, appear to be extending that trend further.

Polynucleotides and emerging regenerative treatments

Among newer treatments, polynucleotides stand out not for their scale, but for the speed at which they have entered public awareness.

Barely visible in search data before late 2023, they have since grown rapidly, moving from near-zero awareness to a small but clearly rising category by 2026. Although they remain far behind established treatments in absolute terms, their growth rate places them among the most dynamic segments in the dataset.

The appeal of polynucleotides sits within a broader shift in how some clinics and manufacturers are positioning aesthetic treatments: less about immediate visible change, more about supporting longer-term skin repair and biological function.

Whether that interest translates into sustained adoption remains uncertain. Many new aesthetic treatments experience early visibility before settling into a more modest long-term level. Still, their trajectory reflects an industry that continues to search for new points of differentiation beyond traditional injectables.

Seasonal patterns and stable technologies

Not all treatments show signs of expansion.

LED light therapy, for example, shows no sustained growth over the period studied. Search interest remains broadly flat overall, although there are predictable seasonal peaks during the winter months, when skincare routines and “self-care” treatments tend to receive more attention.

This pattern is consistent with a category that is well established but no longer expanding in public awareness. Interest appears to rise and fall with seasonal routines rather than reflecting any underlying long-term growth trend.

Reading the wider shift

Search data is an imperfect measure of demand. It captures curiosity and attention rather than bookings or revenue, and it is influenced by media coverage, marketing and social media trends. Even so, the direction of travel is difficult to ignore.

Between late 2023 and mid-2026, Botox remains dominant and continues to grow steadily. Dermal fillers appear largely stable. Microneedling has expanded significantly, and polynucleotides have emerged from a negligible base into a fast-growing niche.

Taken together, these patterns suggest a market that is no longer defined solely by volume-based augmentation. Instead, there is growing emphasis on treatments associated with skin quality, regeneration and longer-term maintenance.

Whether this represents a lasting structural shift or another phase in a constantly evolving industry remains to be seen. But the balance of interest appears to be moving, gradually, towards the idea that aesthetic improvement is as much about supporting the skin as it is about changing its shape.